Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
  • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
  • C07D473/28—Oxygen atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/12—Aerosols; Foams
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents

Definitions

• This invention is directed to pharmaceutical compositions, dosage forms, and dosing regimens, in particular to certain discrete and particular dosages of 6-amino-2- ⁇ [(1 S)-1- methylbutyl]oxy ⁇ -9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one, which may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.
• WO 2010/018133 relates to certain purine derivatives disclosed as inducers of human interferon which may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.
• One particular purine derivative disclosed in WO 2010/018133 is 6-amino-2- ⁇ [(1 S)- 1 -methylbutyl]oxy ⁇ -9-[5-(1 -piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one.
• This invention is directed to pharmaceutical dosage forms, means for providing such pharmaceutical dosage forms, pharmaceutical compositions, and dosing regimens for 6- amino-2- ⁇ [(1 S)-1-methylbutyl]oxy ⁇ -9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one ('Compound (I)')
• Compound (I) which may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.
• WO 2010/018133 SmithKline Beecham Corporation
• WO 2010/018133 relates to certain purine derivatives disclosed as inducers of human interferon which may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.
• One particular purine derivative disclosed in WO 2010/018133 is 6-amino-2- ⁇ [(1 S)- 1 -methylbutyl]oxy ⁇ -9-[5-(1 -piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one.
• Compound (I) may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.
• a pharmaceutical dosage form comprising Compound (I), or a pharmaceutically acceptable salt thereof, and means for providing a metered-dose of Compound (I), or a pharmaceutically acceptable salt thereof.
• a suitable pharmaceutical dosage form provides 0.5 nanogramme to 20000 nanogrammes of Compound (I) per actuation of the metering means, for example 0.5 nanogramme to 5 microgrammes, for example 1 nanogramme to 5 microgrammes, for example 0.5
• nanogramme to 999 nanogrammes for example 1 nanogramme to 999 nanogrammes.
• a pharmaceutical composition comprising Compound (I) or a pharmaceutically acceptable salt thereof, characterised in that the pharmaceutical composition is suitable for use with metering means.
• a method of treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and allergic asthma, which method comprises the administration of Compound (I), or a pharmaceutically acceptable salt thereof, in an amount equivalent to 0.5 nanogramme to 40000 nanogrammes of Compound (I), for example 1 nanogramme to 20000 nanogrammes, for example 2 nanogrammes to 20000 nanogrammes, for example 1 nanogramme to 4000 nanogrammes, for example 2 nanogrammes to 4000 nanogrammes, for example 1 nanogramme to 999 nanogrammes, for example 2 nanogrammes to 999 nanogrammes, to a human in need thereof.
• Compound (I) or a pharmaceutically acceptable salt thereof for use in treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma, characterised in that 0.5 nanogramme to 40000 nanogrammes, for example 1 nanogramme to 20000 nanogrammes, for example 2 nanogrammes to 20000 nanogrammes, for example 1 nanogramme to 4000 nanogrammes, for example 2 nanogrammes to 4000 nanogrammes, for example 1 nanogramme to 999 nanogrammes, for example 2 nanogrammes to 999 nanogrammes, of Compound (I) is administered to a human in need thereof.
• 0.5 nanogramme to 40000 nanogrammes for example 1 nanogramme to 20000 nanogrammes, for example 2 nanogrammes to 20000 nanogrammes, for example 1 nanogramme to 4000 nanogrammes, for example 2 nanogrammes to 4000 nanogrammes, for example 1 nanogramme to 999 nanogrammes, for example 2 nanogrammes to 999
• Examples of doses of Compound (I) are 0.5 nanogramme, 1 nanogramme, 2 nanogrammes, 5 nanogrammes, 10 nanogrammes, 20 nanogrammes, 30 nanogrammes, 40 nanogrammes, 50 nanogrammes, 60 nanogrammes, 70 nanogrammes, 80 nanogrammes, 90
• a desired dose of Compound (I) may be provided by one or two actuations of the metering means as appropriate given the amount of the pharmaceutical composition dispensed per actuation of the metering means, and the concentration of the pharmaceutical composition being dispensed.
• two actuations of the metering means may be used.
• Suitable pharmaceutically acceptable salts of Compound (I) include those described in WO 2010/018133 and a maleate salt.
• the pharmaceutically acceptable salt is a maleate salt, in particular the 1 :1 maleate salt.
• compositions comprising Compound (I), or a pharmaceutically acceptable salt thereof, are suitably administered by the intranasal or inhaled route.
• compositions for intranasal administration include aqueous compositions administered to the nose by drops or by pressurised pump. Suitable compositions contain water as the diluent or carrier for this purpose. Compositions for administration to the lung or nose may contain one or more excipients, for example one or more suspending agents, one or more preservatives, one or more surfactants, one or more tonicity adjusting agents, one or more co-solvents, and may include components to control the pH of the composition, for example a buffer system. Further, the compositions may contain other excipients such as
• compositions may also be administered to the nose or other regions of the respiratory tract by nebulisation.
• Intranasal compositions may permit the compound(s) of formula (I) or (a) pharmaceutically acceptable salt(s) thereof to be delivered to all areas of the nasal cavities (the target tissue) and further, may permit the compound(s) of formula (I) or (a) pharmaceutically acceptable salt(s) thereof to remain in contact with the target tissue for longer periods of time.
• a suitable dosing regimen for intranasal compositions would be for the patient to inhale slowly through the nose subsequent to the nasal cavity being cleared. During inhalation the composition would be administered to one nostril while the other is manually compressed. This procedure may be repeated for the other nostril.
• the suspending agent(s), if included, will typically be present in an amount of from 0.1 to 5% (w/w), such as from 1.5% to 2.4% (w/w), based on the total weight of the composition.
• examples of pharmaceutically acceptable suspending agents include, but are not limited to, Avicel ® (microcrystalline cellulose and carboxymethylcellulose sodium),
• compositions for administration to the lung or nose may contain one or more excipients may be protected from microbial or fungal contamination and growth by inclusion of one or more preservatives.
• pharmaceutically acceptable anti-microbial agents or preservatives include, but are not limited to, quaternary ammonium compounds (for example benzalkonium chloride, benzethonium chloride, cetrimide, cetylpyridinium chloride, lauralkonium chloride and myristyl picolinium chloride), mercurial agents (for example phenylmercuric nitrate, phenylmercuric acetate and thimerosal), alcoholic agents (for example chlorobutanol, phenylethyl alcohol and benzyl alcohol), antibacterial esters (for example esters of para-hydroxybenzoic acid), chelating agents such as disodium edetate (EDTA) and other anti-microbial agents such as chlorhexidine, chlorocresol, sorbic acid and its salts (such
• Examples of pharmaceutically acceptable anti-fungal agents or preservatives include, but are not limited to, sodium benzoate, sorbic acid, sodium propionate, methylparaben, ethylparaben, propylparaben and butylparaben.
• the preservative(s), if included, may be present in an amount of from 0.001 to 1 % (w/w), such as from 0.015% to 0.5% (w/w) based on the total weight of the composition.
• compositions may include one or more surfactants which functions to facilitate dissolution of the medicament particles in the aqueous phase of the composition.
• the amount of surfactant used is an amount which will not cause foaming during mixing.
• pharmaceutically acceptable surfactants include fatty alcohols, esters and ethers, such as polyoxyethylene (20) sorbitan monooleate (Polysorbate 80), macrogol ethers, and poloxamers.
• the surfactant may be present in an amount of between about 0.01 to 10% (w/w), such as from 0.01 to 0.75% (w/w), for example about 0.5% (w/w), based on the total weight of the composition.
• One or more tonicity-adjusting agent(s) may be included to achieve tonicity with body fluids e.g. fluids of the nasal cavity, resulting in reduced levels of irritancy.
• pharmaceutically acceptable tonicity-adjusting agents include, but are not limited to, sodium chloride, dextrose, xylitol, calcium chloride, glucose, glycerine and sorbitol.
• a tonicity- adjusting agent, if present, may be included in an amount of from 0.1 to 10% (w/w), such as from 4.5 to 5.5% (w/w), for example about 5.0% (w/w), based on the total weight of the composition.
• compositions of the invention may be buffered by the addition of suitable buffering agents such as sodium citrate, citric acid, trometamol, phosphates such as disodium phosphate (for example the dodecahydrate, heptahydrate, dihydrate and anhydrous forms), or sodium phosphate and mixtures thereof.
• suitable buffering agents such as sodium citrate, citric acid, trometamol, phosphates such as disodium phosphate (for example the dodecahydrate, heptahydrate, dihydrate and anhydrous forms), or sodium phosphate and mixtures thereof.
• a buffering agent if present, may be included in an amount of from 0.1 to 5% (w/w), for example 1 to 3% (w/w) based on the total weight of the composition.
• taste-masking agents include sucralose, sucrose, saccharin or a salt thereof, fructose, dextrose, glycerol, corn syrup, aspartame, acesulfame-K, xylitol, sorbitol, erythritol, ammonium glycyrrhizinate, thaumatin, neotame, mannitol, menthol, eucalyptus oil, camphor, a natural flavouring agent, an artificial flavouring agent, and combinations thereof.
• co-solvent(s) may be included to aid solubility of the medicament compound(s) and/or other excipients.
• pharmaceutically acceptable co-solvents include, but are not limited to, propylene glycol, dipropylene glycol, ethylene glycol, glycerol, ethanol, polyethylene glycols (for example PEG300 or PEG400), and methanol.
• the co-solvent is propylene glycol.
• Co-solvent(s), if present, may be included in an amount of from 0.05 to 30% (w/w), such as from 1 to 25% (w/w), for example from 1 to 10% (w/w) based on the total weight of the composition.
• compositions for inhaled administration include aqueous, organic or aqueous/organic mixtures, dry powder or crystalline compositions administered to the respiratory tract by pressurised pump or inhaler, for example, reservoir dry powder inhalers, unit-dose dry powder inhalers, pre-metered multi-dose dry powder inhalers, nasal inhalers, nebulisers, or insufflators.
• Suitable compositions contain water as the diluent or carrier for this purpose and may be provided with conventional excipients such as buffering agents, tonicity modifying agents and the like.
• Aqueous compositions may also be administered to the nose and other regions of the respiratory tract by nebulisation. Such compositions may be aqueous solutions or suspensions.
• compositions for administration topically to the nose or to the lung include aqueous compositions delivered to the nasal cavities by pressurised pump. Suitable compositions contain water as the diluent or carrier for this purpose. Aqueous compositions for administration to the lung or nose may be provided with conventional excipients such as buffering agents, tonicity-modifying agents and the like. Aqueous compositions may also be administered to the nose by nebulisation.
• a fluid dispenser may typically be used to deliver a fluid composition to the nasal cavities.
• the fluid composition may be aqueous or non-aqueous, but typically aqueous.
• Such a fluid dispenser may have a dispensing nozzle or dispensing orifice through which a metered dose of the fluid composition is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser.
• Such fluid dispensers are generally provided with a reservoir of multiple metered doses of the fluid composition, the doses being dispensable upon sequential pump actuations.
• the dispensing nozzle or orifice may be configured for insertion into the nostrils of the user for spray dispensing of the fluid composition into the nasal cavity.
• a fluid dispenser of the aforementioned type is described and illustrated in International Patent Application publication number WO 2005/044354 (Glaxo Group
• the dispenser has a housing which houses a fluid-discharge device having a compression pump mounted on a container for containing a fluid composition.
• the housing has at least one finger-operable side lever which is movable inwardly with respect to the housing to move the container upwardly in the housing by means of a cam to cause the pump to compress and pump a metered dose of the composition out of a pump stem through a nasal nozzle of the housing.
• the fluid dispenser is of the general type illustrated in Figures 30-40 of WO 2005/044354.
• Aqueous compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof may also be delivered by a pump as disclosed in International Patent Application publication number WO 2007/138084 (Glaxo Group Limited), for example as disclosed with reference to Figures 22-46 thereof.
• Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator.
• Powder blend compositions generally contain a powder mix for inhalation of the compound of formula (I) or a
• carrier/diluent/excipient substance such as mono-, di-, or polysaccharides (for example lactose or starch).
• Dry powder compositions may also include, in addition to the drug and carrier, a further excipient (for example a ternary agent such as a sugar ester for example cellobiose octaacetate, calcium stearate, or magnesium stearate.
• a further excipient for example a ternary agent such as a sugar ester for example cellobiose octaacetate, calcium stearate, or magnesium stearate.
• a composition suitable for inhaled administration may be incorporated into a plurality of sealed dose containers provided on medicament pack(s) mounted inside a suitable inhalation device.
• the containers may be rupturable, peelable, or otherwise openable one-at-a-time and the doses of the dry powder composition administered by inhalation on a mouthpiece of the inhalation device, as known in the art.
• the medicament pack may take a number of different forms, for instance a disk-shape or an elongate strip.
• Representative inhalation devices are the DISKHALERTM and DISKUSTM devices, marketed by GlaxoSmithKline.
• a dry powder inhalable composition may also be provided as a bulk reservoir in an inhalation device, the device then being provided with a metering mechanism for metering a dose of the composition from the reservoir to an inhalation channel where the metered dose is able to be inhaled by a patient inhaling at a mouthpiece of the device.
• exemplary marketed devices of this type are TURBUHALERTM (AstraZeneca), TWISTHALERTM (Schering) and CLICKHALERTM (Innovata.)
• a further delivery method for a dry powder inhalable composition is for metered doses of the composition to be provided in capsules (one dose per capsule) which are then loaded into an inhalation device, typically by the patient on demand.
• the device has means to rupture, pierce or otherwise open the capsule so that the dose is able to be entrained into the patient's lung when they inhale at the device mouthpiece.
• ROTAHALERTM GaxoSmithKline
• HANDIHALERTM Boehringer Ingelheim.
• a suitable metering means is a pump providing a pre-set amount of the pharmaceutical dosage form per actuation, for example 50 microlitres per actuation or 100 microlitres per actuation.
• a suitable pump is a Valois VP7 spray pump (Valois Pharm, Route des Falaises, 27100 Le Vaudreuil, France).
• a suitable pharmaceutical composition for intranasal administration comprising Compound (I), or a pharmaceutically acceptable salt thereof, which is suitable for use with a metering means is a suspension or solution, for example an aqueous solution.
• the pharmaceutical composition may contain from 0.01 to 1000 microgrammes of Compound (I) per millilitre, for example 0.01 microgrammes to 100 microgrammes of Compound (I) per millilitre.
• composition for intranasal administration comprising Compound (I), or a pharmaceutically acceptable salt thereof, suitable for use with a metering means
• a container suitable for the containment and storage of the composition which container is adapted to receive the metering means, for example a Type 1 amber glass bottle (available, for example, from Saint Gobain Desjonqueres (SGD), Avenue Pierre et Marie Curie, Mers-les-Bains, Picardie, France, 80350.)
• composition of the invention may be administered once per week, for example one actuation of the metering means to each nostril per week, for 6 weeks.
• the components other than Compound (I), or a pharmaceutically acceptable salt thereof, used to prepare these compositions are commercially available, for example Sodium
• Chloride Ph. Eur. or USP e.g. Morton Salt, 123 N. Wacker Drive, Chicago, IL, 60606, US
• Benzalkonium Chloride Solution Ph. Eur. or USP e.g. Merck Chemicals LTD., Boulevard Industrial Park, Padge Road, Beeston, Nottingham NG9 2JR, UK
• Disodium Edetate Ph. Eur. or USP e.g. Dow Chemical Co, Seal Sands, Middlesbrough, Cleveland, TS2 1 UD, UK).
• scalar amounts including microgramme amounts, nanogramme amounts and % weight amounts, of 'Compound (I), or a pharmaceutically acceptable salt thereof
• the scalar amount referred to is made in respect of Compound (I) per se.
• 1 .3 nanogrammes of Compound (I) in the form of the 1 :1 maleate salt is that amount of maleate salt which contains 1 nanogramme of Compound
• Compound (I) exists in tautomeric forms. It will be understood that the present invention encompasses all of the tautomers of Compound (I) whether as individual tautomers or as mixtures thereof.
• Compound (I) or a pharmaceutically acceptable salt thereof may be prepared using known methods, for example those disclosed in WO 2010/018133.
• a maleate salt of Compound (I) may be prepared from Compound (I) by reacting 6-amino-2- ⁇ [(1 S)-1-methylbutyl]oxy ⁇ -9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one with maleic acid, in a suitable solvent to produce 6-amino-2- ⁇ [(1 S)-1 -methylbutyl]oxy ⁇ -9-[5-(1 - piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one in the form of a maleate salt.
• the process produces a 1 :1 ratio of maleic acid:6-amino-2- ⁇ [(1 S)-1 -methylbutyl]oxy ⁇ -9-[5-(1- piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one.
• compositions of the invention may be prepared and formulated according to conventional methods such as those disclosed in the British, European, and United States Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press), and Harry's Cosmeticology (Leonard Hill Books).
• compositions for intranasal administration are typically prepared from a concentrated solution by serial dilution.
• the components of the formulation are dissolved in purified water and mixed to provide a concentrated solution of Compound (I) or a
• a placebo solution is also prepared in a similar manner to the concentrated solution, but without Compound (I) or a pharmaceutically acceptable salt thereof.
• the concentrated solution is diluted with the placebo solution to provide formulations of the desired
• Disodium edetate Dissolve the disodium (0.15g) edetate in purified
• 6-Amino-2- ⁇ [(1 S)-1 -methylbutyl]oxy ⁇ -9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (for example, as prepared for Reference Example 1 ) (0.384 g, 0.98 mmol) was dissolved in isopropyl alcohol (4.6 ml_, 12 vols) and heated to 40 °C. Maleic acid (0.1 14 g, 0.98 mmol) was added. A clear solution was obtained. During cooling to room temperature, precipitation occurred. The slurry was filtered, washed with /so-propyl alcohol (5 mL) and dried under reduced pressure at 40°C to constant weight.
• the resulting slurry was cooled to room temperature and held overnight (approximately 16 hours), then cooled in an ice/water bath for 30 minutes.
• the slurry was filtered, washing with /so-propyl alcohol (4.5 mL, 3 vols and then 3 mL, 2 vols).
• the product was dried under reduced pressure at 40°C to constant weight to give 6-amino-2- ⁇ [(1 S)-1-methylbutyl]oxy ⁇ -9-[5-(1-piperidinyl) pentyl]- 7,9-dihydro-8H-purin-8-one, maleate salt (1.305 g, 69% th).
• Example 1 Composition of Nasal Spray Solution containing Compound (I) at Q.01 mg/mL, 0.1 mg/mL and 1 mg/mL
• the quantity of Compound (I) may be adjusted to reflect the assigned purity of the input drug substance (Compound (I) as 1 :1 maleate salt). Salt to base factor is 1 .3
• the quantity of Compound (I) may be adjusted to reflect the assigned purity of the input drug substance (Compound (I) as 1 : 1 maleate salt). Salt to base factor is 1 .3
• Example 3 Composition of Nasal Spray Solution containing Compound (I) at 100mq/mL
• the quantity of Compound (I) may be adjusted to reflect the assigned purity of the input drug substance (Compound (I) as 1 :1 maleate salt). Salt to base factor is 1.3

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Dispersion Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pulmonology (AREA)
• Otolaryngology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Immunology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (20)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=46581948

Family Applications (1)

Country Status (20)

Families Citing this family (6)

Citations (4)

Family Cites Families (82)

• 2012
  • 2012-07-19 CA CA2841361A patent/CA2841361A1/en not_active Abandoned
  • 2012-07-19 HR HRP20181667TT patent/HRP20181667T1/hr unknown
  • 2012-07-19 ES ES12740119.8T patent/ES2693122T3/es active Active
  • 2012-07-19 CN CN201280036096.6A patent/CN103841958A/zh active Pending
  • 2012-07-19 US US14/234,070 patent/US10112946B2/en not_active Expired - Fee Related
  • 2012-07-19 KR KR1020147004436A patent/KR101916928B1/ko not_active Expired - Fee Related
  • 2012-07-19 DK DK12740119.8T patent/DK2734186T3/en active
  • 2012-07-19 BR BR112014001425A patent/BR112014001425A2/pt not_active IP Right Cessation
  • 2012-07-19 JP JP2014520661A patent/JP2014520874A/ja active Pending
  • 2012-07-19 LT LTEP12740119.8T patent/LT2734186T/lt unknown
  • 2012-07-19 AU AU2012289042A patent/AU2012289042A1/en not_active Abandoned
  • 2012-07-19 SI SI201231421T patent/SI2734186T1/sl unknown
  • 2012-07-19 RU RU2013157398A patent/RU2631482C2/ru not_active IP Right Cessation
  • 2012-07-19 EP EP12740119.8A patent/EP2734186B1/en active Active
  • 2012-07-19 PL PL12740119T patent/PL2734186T3/pl unknown
  • 2012-07-19 SM SM20180642T patent/SMT201800642T1/it unknown
  • 2012-07-19 PT PT12740119T patent/PT2734186T/pt unknown
  • 2012-07-19 RS RS20181346A patent/RS57995B1/sr unknown
  • 2012-07-19 WO PCT/EP2012/064139 patent/WO2013014052A1/en not_active Ceased
• 2016
  • 2016-04-20 AU AU2016202513A patent/AU2016202513B2/en not_active Ceased
• 2018
  • 2018-09-27 US US16/143,969 patent/US20190023707A1/en not_active Abandoned
  • 2018-10-31 CY CY181101125T patent/CY1120802T1/el unknown

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events